Investigational drug · Phase 2
Boserolimab
Also called: MK-5890
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung, Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
5
Any phase or sponsor naming "Boserolimab"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Boserolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Boserolimab" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165070 · 450 participants (planned) · Start Dec 19, 2019 · Primary completion Feb 13, 2032
Drug: Pembrolizumab; Carboplatin and 8 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 47 sites in all
- Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03396445 · 182 participants · Start Feb 18, 2018 · Primary completion Sep 27, 2024
Drug: Boserolimab; Pembrolizumab and 3 more · For: Pharmacokinetics; Solid Tumor; Carcinoma, Non-Small-Cell Lung and 1 more
Sites: Mobile, Alabama; Sarasota, Florida; Germantown, Tennessee · 18 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165096 · 128 participants · Start Jan 21, 2020 · Primary completion Apr 30, 2025
Drug: Pembrolizumab; Boserolimab and 4 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 39 sites in all
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04924101 · 122 participants · Start Jul 15, 2021 · Primary completion Jun 23, 2025
Drug: Pembrolizumab; MK-4830 and 5 more · For: Small Cell Lung Cancer
Sites: Gilbert, Arizona; Aurora, Colorado; Atlanta, Georgia · 49 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06829199 · 0 participants · Start Mar 26, 2025 · Primary completion Jan 18, 2029
Drug: Pembrolizumab; Paclitaxel and 7 more · For: Early Triple Negative Breast Cancer
Sites: Las Vegas, Nevada; Tainan, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies.
Dang X, Guelen L, Lutje Hulsik D, et al. · MAbs 2023
- Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L, Fischmann TO, Wong J, et al. · J Immunother Cancer 2022
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.